- TSX.V: DXD
- OTCQB: TDSGF FSE: 3D0
T 604 428 8842
Stock Information (as of December 5, 2017)
|Issued and Outstanding Shares||56,308,616|
|Fully Diluted Shares||84,054,795|
Proprietary 3D imaging technology could represent a major medical advancement in patient diagnosis, treatment and the development of companion diagnostics to personalize patient treatment.
ATTRACTING INDUSTRY MAJORS
Highly promising and unconventional software platform is already attracting attention from multinational healthcare companies relatively early in the product development process.
EXCEPTIONAL TIMING AHEAD OF IMPORTANT CATALYSTS
Steady stream of positive news flow expected including talent acquisition, clinical trial progress and new business developments
SOFTWARE AS A SERVICE (SaaS) MODEL
Building a highly scalable SaaS based business with high margins and low overhead. Proprietary software never leaves the Company’s server while raw digital data can be collected and analyzed from partner labs located around the world.
EXPERT TEAM WITH SUCCESSFUL TRACK RECORD IN BIOMEDICAL MARKET
Accomplished leadership with the ability to develop and commercialize new products and secure strategic partnerships.
STRONG FISCAL MANAGEMENT
Drive growth through strategic allocation of capital. Control expenses through sensible fiscal management and streamlined operations.